Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORBIT-EXPANSE long-term extension study of navenibart in hereditary angioedema
2025-521142-22-00Phase 3Authorised
- Sponsor
- Astria Therapeutics
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 23
01
Overview
Phase 3, open-label trial of navenibart in hereditary angioedema (HAE) (2 arms), sponsored by Astria Therapeutics. Primary endpoint: Incidence of treatment-emergent adverse events. Planned start Mar 2026; status: authorised.
02
Drugs
navenibart
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2025-521142-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521142-22-00.